ALNY Q3 2024 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$501M-33.3% YoY

Gross Profit

$415M82.9% margin

Operating Income

-$77M-15.4% margin

Net Income

-$112M-22.3% margin

EPS (Diluted)

$-0.87

QoQ Revenue Growth

-24.1%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$40M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$4.2B

Total Liabilities

$4.2B

Stockholders' Equity

$32M

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$501M	$751M	-33.3%
Gross Profit	$415M	$666M	-37.7%
Operating Income	-$77M	$214M	-136.0%
Net Income	-$112M	$148M	-175.5%

Revenue Segments

Product

$420M78%

GIVLAARI

$71M13%

ONPATTRO

$50M9%

Geographic Segments

UNITED STATES

$169M65%

Europe

$65M25%

Non-US Or Europe

$25M10%